Abstract 2792
Background
Patient education is quite a current notion that has proved its efficiency. It has been shown as discussed in previous sections that it improves quite significantly treatment outcomes. Through education and support programs, patients health literacy is improved and so is the adherence of treatment. In this light, an education and support program was adapted at the Mohamed VI center for cancer treatment in Casablanca, with the following objectives: 1. Improve patient’s adherence to treatment 2. Increase early detection of chemotherapy side effects between cures 3. Improve quality of life and avoid toxic deaths.
Methods
In total, 96 patients were included into the program for a period of one year (February 2017- February 2018) and their satisfaction evaluated.
Results
In total, 96 patients were included into the program for a period of one year (February 2017- February 2018) and their satisfaction evaluated. 86,5% of the respondents were female while 13,5% were male. Of this, 70,8 % were literate while 29,2% were illetrate. Most of them, 57,2% had some awareness about cancer before they were included into the program while the rest , 42,8% had no cancer awareness. Most of the patients, 86,5% found that the videos and flyers were easy to understand while 80,2% reported that the same was helpful. 76% of the respondents admitted that the program had helped them become more proactive in their treatment. 78,1% of them were satisfied with the mobile phone calls in managing their complications at home without necessaroly coming to the hospital. 99% of the patients said that they would likely recommend the program to other patients. In overall, 87,5% of the patients were satisfied with the education program while only 3,1 % were dissatisfied. The rest of the respondents, 9,3% were neither satisfied nor dissatisfied.
Conclusions
At the end of the study, our findings were generally comparable to those in the literature and all the indicators were achieved. Therefore, this pilot program should be fully implemented.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3212 - Multigene panel testing results for hereditary breast cancer in 1325 individuals: implications for gene selection and considerations for guidelines.
Presenter: Georgios Tsaousis
Session: Poster Display session 3
Resources:
Abstract
2591 - PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors
Presenter: Julia Quintanilha
Session: Poster Display session 3
Resources:
Abstract
4377 - ERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine therapy (ET): a retrospective analysis of the ALTERNATIVE and SOLTI-PAMELA trials.
Presenter: Nuria Chic
Session: Poster Display session 3
Resources:
Abstract
3439 - Early on-treatment vs pre-treatment tumor transcriptomes as predictors of response to neoadjuvant therapy for HER2-positive inflammatory breast cancer
Presenter: Sonia Pernas
Session: Poster Display session 3
Resources:
Abstract
2512 - AXL expression predicts poor prognosis and lack of efficacy of anti-angiogenic and anti-epidermal growth factor receptor (EGFR) agents in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC)
Presenter: Claudia Cardone
Session: Poster Display session 3
Resources:
Abstract
4061 - Prevalence of EGFR mutations and its correlation with Egyptian patients’ human kinetics (PEEK Study)
Presenter: Adel Ibrahim
Session: Poster Display session 3
Resources:
Abstract
2547 - Evaluation of tumor microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ gastroesophageal adenocarcinoma (GEA)
Presenter: Sergio Rutella
Session: Poster Display session 3
Resources:
Abstract
4671 - Clinicopathological and molecular criteria assessment for the screening of hypermutated proficient mismatch repair (pMMR) colorectal cancers (CRC) with exonucleasic domain POLE (edPOLE) mutations (mt).
Presenter: Benoit Rousseau
Session: Poster Display session 3
Resources:
Abstract
3862 - Tumor mutation burden and microsatellite instability in colorectal cancer
Presenter: Francesca Fenizia
Session: Poster Display session 3
Resources:
Abstract
4614 - Predictors of Response to Checkpoint Inhibitors in Naïve and Ipilimumab-Refractory Melanoma
Presenter: Domenico Mallardo
Session: Poster Display session 3
Resources:
Abstract